- Home
- SLRX vs INM Comparison
SLRX vs INM Comparison
Compare SLRX & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRX
- INM
- Stock Information
- Founded
- SLRX N/A
- INM 1981
- Country
- SLRX United States
- INM Canada
- Employees
- SLRX N/A
- INM N/A
- Industry
- SLRX Biotechnology: Pharmaceutical Preparations
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- SLRX Health Care
- INM Health Care
- Exchange
- SLRX Nasdaq
- INM Nasdaq
- Market Cap
- SLRX 2.1M
- INM 2.3M
- IPO Year
- SLRX N/A
- INM N/A
- Fundamental
- Price
- SLRX $1.34
- INM $3.12
- Analyst Decision
- SLRX
- INM
- Analyst Count
- SLRX 0
- INM 0
- Target Price
- SLRX N/A
- INM N/A
- AVG Volume (30 Days)
- SLRX 71.1K
- INM 84.1K
- Earning Date
- SLRX 03-21-2025
- INM 02-12-2025
- Dividend Yield
- SLRX N/A
- INM N/A
- EPS Growth
- SLRX N/A
- INM N/A
- EPS
- SLRX N/A
- INM N/A
- Revenue
- SLRX N/A
- INM $4,832,013.00
- Revenue This Year
- SLRX N/A
- INM N/A
- Revenue Next Year
- SLRX N/A
- INM N/A
- P/E Ratio
- SLRX N/A
- INM N/A
- Revenue Growth
- SLRX N/A
- INM N/A
- 52 Week Low
- SLRX $1.22
- INM $2.42
- 52 Week High
- SLRX $7.20
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- SLRX 32.32
- INM 37.82
- Support Level
- SLRX $2.08
- INM $3.03
- Resistance Level
- SLRX $1.94
- INM $3.48
- Average True Range (ATR)
- SLRX 0.14
- INM 0.20
- MACD
- SLRX -0.09
- INM 0.05
- Stochastic Oscillator
- SLRX 2.80
- INM 35.59
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.